SLNO Soleno Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SLNO

Price (delayed)

$45.12

Market cap

$1.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.36

Enterprise value

$1.3B

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet ...

Highlights
The EPS is up by 26% since the previous quarter and by 18% year-on-year
SLNO's debt has surged by 160% year-on-year but it is down by 14% since the previous quarter
Soleno Therapeutics's net income has plunged by 62% YoY and by 18% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://soleno.life
Peers: OMER OMGA

Key stats

What are the main financial stats of SLNO
Market
Shares outstanding
32.46M
Market cap
$1.46B
Enterprise value
$1.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$38.99M
EBITDA
-$36.71M
Free cash flow
-$24.94M
Per share
EPS
-$2.36
Free cash flow per share
-$1.51
Book value per share
$5.16
Revenue per share
$0
TBVPS
$10.43
Balance sheet
Total assets
$180.69M
Total liabilities
$23.18M
Debt
$403,000
Equity
$157.51M
Working capital
$159.85M
Liquidity
Debt to equity
0
Current ratio
14.89
Quick ratio
14.75
Net debt/EBITDA
4.61
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-52.9%
Return on equity
-79.7%
Return on invested capital
N/A
Return on capital employed
-23%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SLNO stock price

How has the Soleno Therapeutics stock price performed over time
Intraday
-8.35%
1 week
19.08%
1 month
8.05%
1 year
1,160.34%
YTD
12.1%
QTD
5.42%

Financial performance

How have Soleno Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.67M
Net income
-$38.99M
Gross margin
N/A
Net margin
N/A
Soleno Therapeutics's net income has plunged by 62% YoY and by 18% from the previous quarter
The operating income has plunged by 54% YoY and by 21% from the previous quarter

Growth

What is Soleno Therapeutics's growth rate over time

Valuation

What is Soleno Therapeutics stock price valuation
P/E
N/A
P/B
8.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 26% since the previous quarter and by 18% year-on-year
The price to book (P/B) is 99% higher than the 5-year quarterly average of 4.4 and 17% higher than the last 4 quarters average of 7.5

Efficiency

How efficient is Soleno Therapeutics business performance
The ROE has soared by 71% from the previous quarter and by 40% YoY
The company's return on assets rose by 44% QoQ and by 24% YoY

Dividends

What is SLNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLNO.

Financial health

How did Soleno Therapeutics financials performed over time
SLNO's total assets has soared by 184% since the previous quarter
The total liabilities has increased by 44% YoY but it has decreased by 43% QoQ
SLNO's debt is 100% smaller than its equity
SLNO's debt has surged by 160% year-on-year but it is down by 14% since the previous quarter
The company's debt to equity has shrunk by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.